{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00022953", "CSN": null, "TRF": "ORD_1445643_01", "MRN": "8879161", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1189274", "clinicalId": "1190644", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1445643_01", "SampleName": "US1385415.01", "Version": "0", "Sample": {"FM_Id": "ORD_1445643_01", "SampleId": "US1385415.01", "BlockId": "S111-31320A", "TRFNumber": "ORD_1445643_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2022_08_30", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "30", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-97882", "MRN": "8879161", "FullName": "\u5433\u5fd7\u826f", "FirstName": "Chih_Liang", "LastName": "Wu", "SubmittedDiagnosis": "Squamous cell carcinoma, Anus", "Gender": "Male", "DOB": "1950_03_12", "OrderingMD": "\u9127\u8c6a\u5049", "OrderingMDId": "109266", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Anus", "CollDate": "2022_08_12", "ReceivedDate": "2022-09-13 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Carcinoma, NOS"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "15", "clinicalTrialCount": "6", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "EED", "isVUS": "true", "variantName": "amplification"}, {"geneName": "IRS2", "isVUS": "true", "variantName": "A512T"}, {"geneName": "MEN1", "isVUS": "true", "variantName": "amplification"}, {"geneName": "MKNK1", "isVUS": "true", "variantName": "R443H"}, {"geneName": "POLD1", "isVUS": "true", "variantName": "V124A"}, {"geneName": "SPEN", "isVUS": "true", "variantName": "S2306del"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "CCND1", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "true", "name": "amplification"}}, "Interpretation": "CCND1 encodes cyclin D1, a binding partner of the kinases CDK4 and CDK6, that regulates RB activity and cell cycle progression. Amplification of CCND1 has been positively correlated with cyclin D1 overexpression (Elsheikh et al., 2008; 17653856) and may lead to excessive proliferation (Fu et al., 2004; 15331580, Takahashi_Yanaga and Sasaguri, 2008; 18023328). The 11q13 amplicon, containing CCND1, FGF3, FGF4, and FGF10, was detected in 9% of anal squamous cell carcinomas (SCCs) in one study involving 70 patients (Chung et al., 2016; 27052656). Another study did not detect CCND1 amplification in any of 24 anal SCCs analyzed; however, weak cyclin D1 expression was observed in 8% of cases (Sheyn et al., 1997; 9042789). Other studies have reported cyclin D1 expression in approximately 33% (7/21) to 34% (33/98) of anal carcinoma samples (L\u00ea et al., 2005; 15923158, Allal et al., 2004; 15292923). Published data investigating the prognostic implications of CCND1 alterations in anal carcinoma are limited (PubMed, Jul 2022). Amplification or overexpression of CCND1 may predict sensitivity to CDK4/6 inhibitors, such as abemaciclib, palbociclib, and ribociclib (Juric et al., 2016; ASCO Abstract 568, Peguero et al., 2016; ASCO Abstract 2528, Tolaney et al., 2016; SABCS P4_22_12, Morschhauser et al., 2020; 32381571, Flaherty et al., 2012; 22090362, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Patnaik et al., 2016; 27217383, Leonard et al., 2012; 22383795), although as monotherapy these agents have shown limited activity in tumor types other than breast cancer (Dickler et al., 2017; 28533223, Patnaik et al., 2016; 27217383). In refractory advanced solid tumors with CCND1 (n=39) or CCND3 (n=1) amplification and retinoblastoma protein expression, palbociclib resulted in SD for 39% (14/36) of patients and a median PFS of 1.8 months in the NCI_MATCH trial (Clark et al., 2019; AACR Abstract LB_010/2); 4 patients (13%, 4/36 overall) with squamous cell carcinomas (lung, esophageal, or laryngeal) or adenoid cystic carcinoma experienced prolonged SD in this study (Clark et al., 2019; AACR Abstract LB_010/2). Among 9 patients with CCND1_amplified advanced solid tumors, 1 patient with bladder cancer responded to ribociclib in a Phase 2 trial (Peguero et al., 2016; ASCO Abstract 2528).", "Include": "true", "ClinicalTrialNote": "CCND1 amplification or overexpression may activate CDK4/6 and may predict sensitivity to single_agent CDK4/6 inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04282031", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT03297606", "Include": "true"}, {"nctId": "NCT04116541", "Include": "true"}, {"nctId": "NCT05252416", "Include": "true"}, {"nctId": "NCT02896335", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "C11orf30 (EMSY)", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "EMSY, also known as C11orf30, encodes a BRCA2_interacting protein with roles in transcriptional regulation (Varier et al., 2016; 26841866, Hughes_Davies et al., 2003; 14651845). Preclinical studies have suggested that EMSY binds to and suppresses the function of BRCA2, and EMSY overexpression may therefore mimic BRCA2 inactivation (Cousineau and Belmaaza, 2011; 21409565, Hughes_Davies et al., 2003; 14651845). Amplification of the EMSY gene correlates with increased mRNA expression (Wilkerson et al., 2011; 21735447, van Hattem et al., 2008; 18787609), although conflicting data have been reported (Shih et al., 2005; 16172393). The functional consequences of other EMSY alterations have not been extensively studied (PubMed, 2022). In the TCGA datasets, EMSY amplification has been most frequently observed in ovarian carcinoma (8%)(Cancer Genome Atlas Research Network., 2011; 21720365), breast invasive carcinoma (6%)(Cancer Genome Atlas Network., 2012; 23000897), esophageal carcinoma (5%)(cBioPortal, 2022), and head and neck squamous cell carcinoma (3.5%)(HNSCC_Cancer Genome Atlas Network., 2015; 25631445, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). EMSY overexpression has been primarily reported in breast and high grade ovarian cancers, where it is implicated in BRCA2 inactivation and correlates with poor prognosis or advanced disease (Wilkerson et al., 2011; 21735447, Brown et al., 2008; 18314909, Brown et al., 2010; 19636701, Altinisik et al., 2011; 20349280, Madjd et al., 2014; 24641409, Bane et al., 2011; 21327470, Rodriguez et al., 2004; 15355907, Hughes_Davies et al., 2003; 14651845). The consequences of EMSY alterations in other solid tumors or hematologic malignancies have not been studied in detail in the scientific literature (PubMed, 2022). EMSY overexpression in breast cancer cell lines has been reported to mimic the effects of inactivating BRCA2 mutations (Cousineau and Belmaaza, 2011; 21409565). Unlike BRCA2 inactivation, which predicts sensitivity to DNA repair_associated inhibitors such as the PARP inhibitor olaparib (Dedes et al., 2011; 21487248, Ihnen et al., 2013; 23729402), EMSY amplification in breast cancer lines was not associated with enhanced sensitivity to this drug in one preclinical study (Wilkerson et al., 2011; 21735447). There are no therapies that target EMSY alterations.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "CUL4A", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "true", "name": "amplification"}}, "Interpretation": "CUL4A encodes cullin 4A, a core component of an E3 ubiquitin ligase complex that targets proteins for ubiquitin_mediated degradation, regulating critical processes such as cell cycle progression and maintenance of genomic stability (reviewed in Sang et al., 2015; 26460955, Hannah and Zhou, 2015; 26344709, Sharma and Nag, 2014; 24522884). CUL4A overexpression increases cell proliferation and transformation (Gupta et al., 2002; 11849807, Li et al., 2003; 12393421, Hung et al., 2011; 19929949, Ren et al., 2012; 22422151, Saucedo_Cuevas et al., 2014; 24870930, Wang et al., 2014; 24305877, Sui et al., 2017; 28223829). Amplification of CUL4A or the 13q34 genomic region encompassing CUL4A has been correlated with increased CUL4A mRNA and/or protein expression in several cancer types (Melchor et al., 2009; 19995430, Castillo et al., 2010; 20556744, Hung et al., 2011; 19929949, Liu et al., 2015; 26684807, Yang et al., 2015; 26218750, Jia et al., 2017; 27974468). CUL4A amplification and/or overexpression has been reported in breast carcinoma (Chen et al., 1998; 9721878, Abba et al., 2007; 17483321, Schindl et al., 2007; 17465225, Melchor et al., 2009; 19995430, Wang et al., 2014; 24305877, Pfefferle et al., 2016; 27149990), lung carcinoma (Castillo et al., 2010; 20556744, Wang et al., 2014; 25413624, Jia et al., 2017; 27974468), gastric carcinoma (Wang et al., 2014; 24305877, Deng et al., 2016; 26840256, Gong et al., 2017; 28442889), colorectal carcinoma (CRC) (Wang et al., 2014; 24305877, Ren et al., 2016; 27418574, Sui et al., 2017; 28223829), hepatocellular carcinoma (HCC) (Yasui et al., 2002; 12029633, Pan et al., 2015; 26593394), intrahepatic cholangiocarcinoma (Liu et al., 2015; 26684807, Huang et al., 2017; 28576144), malignant pleural mesothelioma (Hung et al., 2011; 19929949, Yang et al., 2015; 26218750), ovarian carcinoma (Birner et al., 2012; 22447918, Wang et al., 2014; 24305877), osteosarcoma (Song et al., 2015; 26055549, Li et al., 2016; 26715273), and other tumor types (Ren et al., 2012; 22422151, Xu et al., 2014; 24420924, Yang et al., 2017; 28677427). In several of these studies, increased CUL4A mRNA and/or protein expression was significantly associated with adverse clinicopathologic features, such as clinical stage, pathological grade, or distant metastasis (Sui et al., 2017; 28223829, Ren et al., 2016; 27418574, Wang et al., 2014; 24305877, Deng et al., 2016; 26840256, Li et al., 2016; 26715273, Song et al., 2015; 26055549, Jia et al., 2017; 27974468, Pan et al., 2015; 26593394, Xu et al., 2014; 24420924, Ren et al., 2012; 22422151). High CUL4A expression has been associated with inferior survival in patients with breast cancer [overall survival (OS), hazard ratio (HR) = 2.10; disease_free survival (DFS), HR = 1.92] (Schindl et al., 2007; 17465225), lung cancer [OS, HR = 1.610; progression_free survival (PFS), HR = 1.739] (Jia et al., 2017; 27974468), intrahepatic cholangiocarcinoma (DFS, HR = 1.688) (Huang et al., 2017; 28576144), or invasive ovarian cancer (OS, HR = 2.387; DFS, HR = 3.5) (Birner et al., 2012; 22447918) in multivariate analyses. There are no approved therapies available to target CUL4A alterations in cancer. Preclinical studies have suggested association of CUL4A expression in cancer cell lines with increased sensitivity to trabectedin (Garc\u00eda et al., 2013; 23364677) or thalidomide (Ren et al., 2012; 22422151) and reduced sensitivity to cisplatin (Yang et al., 2014; 24648314, Englinger et al., 2017; 28095394); gemcitabine (Hung et al., 2016; 26969027, Hung et al., 2015; 26503734); or P_gp substrate drugs paclitaxel, vincristine, and adriamycin (Wang et al., 2013; 24368600), but clinical data supporting these findings are limited.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "FGF19", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "true", "name": "amplification"}}, "Interpretation": "FGF19 encodes fibroblast growth factor 19, an FGFR4 ligand involved with bile acid synthesis and hepatocyte proliferation in the liver (Xie et al., 1999; 10525310, Hagel et al., 2015; 25776529). FGF19 lies in a region of chromosome 11q13 that also contains FGF3, FGF4, and CCND1; this region is frequently amplified in a diverse range of malignancies (Katoh et al., 2002; 12429977). Correlation between FGF19 amplification and protein expression has been reported in hepatocellular carcinoma (HCC)(Kan et al., 2013; 23788652), lung squamous cell carcinoma (Li et al., 2020; 32111983, Caruso et al., 2019; 31063779), and head and neck squamous cell carcinoma (HNSCC)(Gao et al., 2019; 30518874), but was not observed in other cancers (Sawey et al., 2011; 21397858, Kanzaki et al., 2021; 33674622). For patients with solid tumors, FGF19 amplification has been reported most frequently in breast cancer (17%), head and neck cancer (12%), lung squamous cell carcinoma (SCC; 12%), and urothelial carcinoma cancer (11%)(cBio_Zehir et al., 2017; 28481359, cBio_Cancer Genome Atlas Research Network, 2012; 22960745, cBio_Robertson et al., 2017; 28988769). FGF19 mutations are rare in solid tumors (cBio_Zehir et al., 2017; 28481359). FGF19 expression or amplification has been associated with poor prognosis in hepatocellular carcinoma (HCC)(Miura et al., 2012; 22309595, Kang et al., 2019; 30815392), and in prostate cancer following radical prostatectomy (Nagamatsu et al., 2015; 25854696). Studies suggest FGF19 expression may also be a poor prognostic indicator in head and neck squamous cell carcinoma (HNSCC)(Gao et al., 2019; 30518874) and lung SCC (Li et al., 2020; 32111983). A Phase 1 study of the FGFR4 inhibitor fisogatinib (BLU_554) for patients with advanced hepatocellular carcinoma (HCC) reported a 17% ORR (11/66, 1 CR, ongoing for >1.5 years) and 3.3_month PFS for FGF19 IHC\u2013positive patients; patients with negative or unknown FGF19 IHC scores experienced poorer outcomes (0% ORR, 2.3_month PFS)(Kim et al., 2019; 31575541). A Phase 1/2 study evaluating another FGFR4 inhibitor, FGF401, demonstrated an ORR of 7.5% (4/53) and SD rate of 53% (28/53) for patients with HCC (Chan et al., 2017; AACR Abstract CT106). A Phase 1 study of the FGFR4 inhibitor H3B_6527 reported a 17% ORR (OS of 10.3 months, 46% clinical benefit rate) among patients with HCC; enrollment of patients with intrahepatic cholangiocarcinoma (ICC) was suspended due to efficacy (Macarulla et al., 2021; ASCO Abstract 4090). A retrospective analysis reported that 50% (2/4) of patients with HCC harboring FGF19 amplification experienced a CR to sorafenib (Kaibori et al., 2016; 27384874), though another retrospective study found patients with higher pretreatment serum levels of FGF19 experienced reduced benefit from sorafenib compared with those with lower serum FGF19 (PFS of 86 vs. 139 days, OS of 353 vs. 494 days); no difference was observed for lenvatinib (Kanzaki et al., 2021; 33674622). A patient with head and neck squamous cell carcinoma (HNSCC) with 11q13 (FGF3, FGF4, FGF19) and 12p13 (FGF6 and FGF23) amplification experienced a CR lasting 9 months from a pan_FGFR inhibitor (Dumbrava et al., 2018; 31123723).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "FGF3", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "true", "name": "amplification"}}, "Interpretation": "FGF3 encodes fibroblast growth factor 3, a growth factor that plays a central role in development of the inner ear. Germline mutations in FGF3 give rise to an autosomal recessive syndrome characterized by microdontia, deafness, and complete lack of inner ear structures (Tekin et al., 2007; 17236138). FGF3 lies in a region of chromosome 11q13 that also contains FGF19, FGF4, and CCND1, the latter gene encoding cyclin D1, a key regulator of cell cycle progression. This chromosomal region is frequently amplified in a diverse range of malignancies (Fu et al., 2004; 15331580). There are no targeted therapies that directly address genomic alterations in FGF3. Inhibitors of FGF receptors, however, are undergoing clinical trials in a number of different cancers. Limited data suggest that pan_FGFR inhibitors show activity in FGF amplified cancers; following treatment with a selective pan_FGFR inhibitor, a patient with head and neck squamous cell carcinoma (HNSCC) and amplification of 11q13 (FGF3, FGF4, FGF19) and 12p13 (FGF6 and FGF23) experienced a radiologic CR (Dumbrava et al., 2018; doi/full/10.1200/PO.18.00100).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "FGF4", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "true", "name": "amplification"}}, "Interpretation": "FGF4 encodes fibroblast growth factor 4, which plays a central role in development of the teeth (Kratochwil et al., 2002; 12502739) and acts synergistically with other FGFs and SHH (sonic hedgehog) to regulate limb outgrowth in vertebrate development (Scherz et al., 2004; 15256670). FGF4 lies in a region of chromosome 11q13 that also contains FGF19, FGF3, and CCND1, the latter gene encoding cyclin D1, a key regulator of cell cycle progression. Amplification of FGF4, along with that of FGF3, FGF19, and CCND1, has been reported in a variety of cancers (Fu et al., 2004; 15331580, Zaharieva et al., 2003; 14648664, Arai et al., 2003; 14499691, Ribeiro et al., 2014; 24477574, Arao et al., 2013; 22890726, Schulze et al., 2015; 25822088) and may confer sensitivity to the multi_kinase inhibitor sorafenib (Arao et al., 2013; 22890726). FGF4 lies in a region of chromosome 11q13 that also contains FGF19, FGF3, and CCND1, the latter gene encoding cyclin D1, a key regulator of cell cycle progression. This chromosomal region is frequently amplified in a diverse range of malignancies (Fu et al., 2004; 15331580) including esophageal carcinoma (35%), head and neck squamous cell carcinoma (HNSCC; 24%), breast invasive carcinoma (14%), lung squamous cell carcinoma (13%), cholangiocarcinoma (11%), bladder urothelial carcinoma (10%), stomach adenocarcinoma (7%), skin melanoma (5%), and hepatocellular carcinoma (HCC; 5%), however FGF4 amplification is rare in hematopoietic and lymphoid malignancies, reported in less than 1% of samples analyzed (cBioPortal, Jan 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). FGF4 amplification and overexpression was associated with cell sensitivity to the multikinase inhibitor sorafenib in preclinical studies (Arao et al., 2013; 22890726, Yamada et al., 2015; 25885470) and amplification of FGF4/FGF3 in HCC significantly correlated with patient response to sorafenib (p=0.006)(Arao et al., 2013; 22890726). Limited data suggest that pan_FGFR inhibitors show activity in FGF amplified cancers; following treatment with a selective pan_FGFR inhibitor, a patient with head and neck squamous cell carcinoma (HNSCC) and amplification of 11q13 (FGF3, FGF4, FGF19) and 12p13 (FGF6 and FGF23) experienced a radiologic CR (Dumbrava et al., 2018; doi/full/10.1200/PO.18.00100).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "GATA6", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "true", "name": "amplification"}}, "Interpretation": "GATA6 encodes a zinc finger transcription factor, which is involved in the development of several tissues and is expressed in proliferating cells throughout the intestinal tract (Zheng et al., 2010; 21779441). GATA6 has been described as both a tumor suppressor and an oncogene, which may be dependent on the tumor type. Amplification of the GATA6 locus, 18q11.2, has been reported with highest incidences in esophageal adenocarcinomas (21%, 18/85) and pancreatobiliary carcinomas (19%, 7/37)(Lin et al., 2012; 22375031, Kwei et al., 2008; 18535672), and at lower rates in small intestine cancer (5.5%)(Takeda et al., 2022; ASCO GI Abstract 642), urothelial bladder carcinoma (3.9%), lung adenocarcinoma (1.7%), and ovarian carcinoma (1.8%)(cBio_The Cancer Genome Atlas Research Network, 2014; 24476821, cBio_The Cancer Genome Atlas Research Network, 2014; 25079552, cBio_The Cancer Genome Atlas Research Network, 2011; 21720365). While low GATA6 expression correlated with poor prognosis for patients with non_small cell lung cancer (NSCLC) (Yu et al., 2022; DOI: 10.3892/etm.2022.11210, Chen et al., 2020; 32596145), gastric cancer (Liu et al., 2019; 30674866), bladder cancer (Wang et al., 2020; 32103545), or esophageal adenocarcinomas without neoadjuvant treatment (Plum et al., 2021; 33300112), high GATA6 expression has been associated with poor outcome for patients with colon cancer (Shen et al., 2013; 23784465), breast cancer (Song et al., 2015; 26505174), ovarian cancer (Shen et al., 2019; 30633927), cholangiocarcinoma (Tian et al., 2013; 23313142), and NSCLC following EGFR_TKI treatment (Ma et al., 2019; 31092103). There are no targeted therapies available to address genomic alterations in GATA6. Patients with GATA6_high pancreatic tumors exhibited better clinical outcomes following treatment with adjuvant chemotherapy (p=0.003) or first_line folfirinox (HR=1.90, p=0.025) treatment compared with low GATA6 expressing tumors, while no difference was observed for patients treated with gemcitabine (Duan et al., 2021; 34294813, Martinelli et al., 2017; 27325420).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). A study of 8 patients with anal squamous cell carcinoma (SCC), 4 who experienced CR to chemoradiotherapy (CRT) and 4 whose tumors were CRT resistant, reported MSI_low in 2 cases (1 CRT_sensitive and 1 CRT_resistant) and MSS in the other 6; both MSI_low cases were HIV_positive (Gervaz et al., 2001; 11598481). A larger study also did not find MSI_high in any of 40 anal carcinoma cases (Steiniche et al., 2020; 32983568). Published data investigating the prognostic implications of MSI in anal cancer are limited (PubMed, Jul 2022). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "00", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "00"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Squamous cell carcinoma (SCC) of unknown primary harbors a median tumor mutational burden (TMB) of 7.6 Muts/Mb, and 22% of cases have high TMB (>20 Muts/Mb) (FMI_Chalmers et al., 2017; 28420421). High TMB has been reported frequently in skin SCC (67% of cases) (FMI_Chalmers et al., 2017; 28420421, Goodman et al., 2019; 31003990); in 10% of lung SCC (Goodman et al., 2019; 31003990); 8_13% of head and neck SCC cases and non_small cell lung carcinoma, including lung SCC cases (Spigel et al., 2016; ASCO Abstract 9017, FMI_Chalmers et al., 2017; 28420421); and in additional SCC cases, including urothelial (12%), cervical (6.5%), anal (3.8%), and esophageal (2.1%) (Goodman et al., 2019; 31003990). One study of anal carcinomas reported a median tumor mutational burden (mTMB) of 4.4 Muts/Mb, with 14% of cases (17/125) harboring a TMB \u226510 Muts/Mb (Shao et al., 2020; 33119110). Similarly, another study reported that anal squamous cell carcinoma harbors an mTMB of 5.4 Muts/Mb, with 5.6% of cases possessing high TMB (>20 Muts/Mb) (FMI_Chalmers et al., 2017; 28420421). For patients with squamous cell carcinoma (SCC) treated with PD_L1/PD_1 inhibitors, a Kaplan_Meier analysis showed a significant association for patients with high tumor mutational burden (TMB) with longer time to treatment failure (9.9 vs. 4.4 months) (Goodman et al., 2019; 31003990). In the majority of cutaneous SCC cases, high mutational burden has been attributed to UV exposure rather than defective DNA mismatch repair or polymerase activity (South et al., 2014; 24662767, Pickering et al., 2014; 25303977), although one study reported a small number of cutaneous SCC cases (4/39) harboring a mutation signature similar to that of human papillomavirus_positive head and neck SCC (Pickering et al., 2014; 25303977). In patients with non_small cell lung cancer (NSCLC), TMB is similar between cases with squamous and non_squamous histology (Spigel et al., 2016; ASCO Abstract 9017), and increased TMB is associated with higher tumor grade and poor prognosis (Xiao et al., 2016; 27009843), as well as with a decreased frequency of known driver mutations in EGFR, ALK, ROS1, or MET (1% of high_TMB samples each) but not BRAF (10%) or KRAS (9.4%) (Spigel et al., 2016; ASCO Abstract 9017). Although some studies have reported a lack of association between smoking and increased TMB in NSCLC (Schwartz et al., 2016; ASCO Abstract 8533, Xiao et al., 2016; 27009843, Shim et al., 2015; 26200269), several other large studies did find a strong prognostic association (Govindan et al., 2012; 22980976, Ding et al., 2008; 18948947, Imielinski et al., 2012; 22980975, Kim et al., 2014; 24323028). In 1 study, OS did not differ between patients with advanced anal cancer harboring tumor mutational burden (TMB)_high (\u226510 Muts/Mb) or TMB_low (<10 Muts/Mb) who were not previously treated with immunotherapy (Shao et al., 2020; 33119110). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB \u226510 Muts/Mb (as measured by this assay) compared with those with TMB <10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores \u2265 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores <10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB \u2265 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan_solid tumors, where improved ORR and DCR was seen in patients with TMB \u2265 16 Muts/Mb than those with TMB \u2265 10 and <16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386). In the Phase 2 POD1UM_202 study of retifanlimab, an investigational anti_PD_1 antibody, patients with squamous carcinoma of the anal canal experienced an ORR of 14% (13/94, 1 CR), median PFS of 2.3 months, and median OS of 10.1 months (Rao et al., 2020; ESMO Abstract LBA42).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "CCND1", "Alteration": "amplification", "Title": "A Study of BPI_1178 in Patients With Advanced Solid Tumor and HR+/HER2_ Breast Cancer", "StudyPhase": "PHASE 1/2", "Target": "CDK6, CDK4, ER, Aromatase", "Locations": "Shanghai (China)", "NCTID": "NCT04282031", "Note": "CCND1 amplification or overexpression may activate CDK4/6 and may predict sensitivity to single_agent CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND1", "Alteration": "amplification", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "CCND1 amplification or overexpression may activate CDK4/6 and may predict sensitivity to single_agent CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND1", "Alteration": "amplification", "Title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO", "Locations": "Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)", "NCTID": "NCT03297606", "Note": "CCND1 amplification or overexpression may activate CDK4/6 and may predict sensitivity to single_agent CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND1", "Alteration": "amplification", "Title": "A Study Evaluating the Activity of Anti_cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.", "StudyPhase": "PHASE 2", "Target": "CDK6, CDK4, MDM2, MET, ROS1, RET, VEGFRs", "Locations": "Nice (France), Lyon (France), Marseille (France), Toulouse (France), Bordeaux (France)", "NCTID": "NCT04116541", "Note": "CCND1 amplification or overexpression may activate CDK4/6 and may predict sensitivity to single_agent CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND1", "Alteration": "amplification", "Title": "(VELA) Study of BLU_222 in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "ER, CDK4, CDK6, CDK2", "Locations": "Massachusetts, Texas, Florida", "NCTID": "NCT05252416", "Note": "CCND1 amplification or overexpression may activate CDK4/6 and may predict sensitivity to single_agent CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND1", "Alteration": "amplification", "Title": "Palbociclib In Progressive Brain Metastases", "StudyPhase": "PHASE 2", "Target": "CDK4, CDK6", "Locations": "Massachusetts", "NCTID": "NCT02896335", "Note": "CCND1 amplification or overexpression may activate CDK4/6 and may predict sensitivity to single_agent CDK4/6 inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "17653856", "FullCitation": "Elsheikh S, et al. Breast Cancer Res. Treat. (2008) pmid: 17653856", "Include": "true"}, {"number": "1", "ReferenceId": "15331580", "FullCitation": "Fu M, et al. Endocrinology (2004) pmid: 15331580", "Include": "true"}, {"number": "2", "ReferenceId": "18023328", "FullCitation": "Takahashi_Yanaga F, et al. Cell. Signal. (2008) pmid: 18023328", "Include": "true"}, {"number": "3", "ReferenceId": "27052656", "FullCitation": "Chung JH, et al. Ann. Oncol. (2016) pmid: 27052656", "Include": "true"}, {"number": "4", "ReferenceId": "9042789", "FullCitation": "Sheyn I, et al. Hum. Pathol. (1997) pmid: 9042789", "Include": "true"}, {"number": "5", "ReferenceId": "15923158", "FullCitation": "L\u00ea LH, et al. Am. J. Clin. Pathol. (2005) pmid: 15923158", "Include": "true"}, {"number": "6", "ReferenceId": "15292923", "FullCitation": "Allal AS, et al. Br. J. Cancer (2004) pmid: 15292923", "Include": "true"}, {"number": "7", "ReferenceId": "32381571", "FullCitation": "Morschhauser F, et al. Haematologica (2020) pmid: 32381571", "Include": "true"}, {"number": "8", "ReferenceId": "22090362", "FullCitation": "Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362", "Include": "true"}, {"number": "9", "ReferenceId": "25524798", "FullCitation": "Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798", "Include": "true"}, {"number": "10", "ReferenceId": "27542767", "FullCitation": "Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767", "Include": "true"}, {"number": "11", "ReferenceId": "27217383", "FullCitation": "Patnaik A, et al. Cancer Discov (2016) pmid: 27217383", "Include": "true"}, {"number": "12", "ReferenceId": "22383795", "FullCitation": "Leonard JP, et al. Blood (2012) pmid: 22383795", "Include": "true"}, {"number": "13", "ReferenceId": "28533223", "FullCitation": "Dickler MN, et al. Clin. Cancer Res. (2017) pmid: 28533223", "Include": "true"}, {"number": "14", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "15", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "16", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "17", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "18", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "19", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "20", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "21", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "22", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "23", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "24", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "25", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "26", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "27", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "28", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "29", "ReferenceId": "31003990", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31003990", "Include": "true"}, {"number": "30", "ReferenceId": "33119110", "FullCitation": "Shao C, et al. JAMA Netw Open (2020) pmid: 33119110", "Include": "true"}, {"number": "31", "ReferenceId": "24662767", "FullCitation": "South AP, et al. J. Invest. Dermatol. (2014) pmid: 24662767", "Include": "true"}, {"number": "32", "ReferenceId": "25303977", "FullCitation": "Pickering CR, et al. Clin. Cancer Res. (2014) pmid: 25303977", "Include": "true"}, {"number": "33", "ReferenceId": "27009843", "FullCitation": "Xiao D, et al. Oncotarget (2016) pmid: 27009843", "Include": "true"}, {"number": "34", "ReferenceId": "26200269", "FullCitation": "Shim HS, et al. J Thorac Oncol (2015) pmid: 26200269", "Include": "true"}, {"number": "35", "ReferenceId": "22980976", "FullCitation": "Govindan R, et al. Cell (2012) pmid: 22980976", "Include": "true"}, {"number": "36", "ReferenceId": "18948947", "FullCitation": "Ding L, et al. Nature (2008) pmid: 18948947", "Include": "true"}, {"number": "37", "ReferenceId": "22980975", "FullCitation": "Imielinski M, et al. Cell (2012) pmid: 22980975", "Include": "true"}, {"number": "38", "ReferenceId": "24323028", "FullCitation": "Kim Y, et al. J. Clin. Oncol. (2014) pmid: 24323028", "Include": "true"}, {"number": "39", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "40", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "41", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "42", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "43", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "44", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "45", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "46", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "47", "ReferenceId": "30557521", "FullCitation": "Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521", "Include": "true"}, {"number": "48", "ReferenceId": "35101941", "FullCitation": "Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941", "Include": "true"}, {"number": "49", "ReferenceId": "34876409", "FullCitation": "Friedman CF, et al. Cancer Discov (2022) pmid: 34876409", "Include": "true"}, {"number": "50", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "51", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "52", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "53", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "54", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "55", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "56", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "57", "ReferenceId": "11598481", "FullCitation": "Gervaz P, et al. Dis. Colon Rectum (2001) pmid: 11598481", "Include": "true"}, {"number": "58", "ReferenceId": "32983568", "FullCitation": "Steiniche T, et al. Future Sci OA (2020) pmid: 32983568", "Include": "true"}, {"number": "59", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "60", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "61", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "62", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "63", "ReferenceId": "21779441", "FullCitation": "Zheng R, et al. Genes Cancer (2010) pmid: 21779441", "Include": "true"}, {"number": "64", "ReferenceId": "22375031", "FullCitation": "Lin L, et al. Proc Natl Acad Sci U S A (2012) pmid: 22375031", "Include": "true"}, {"number": "65", "ReferenceId": "18535672", "FullCitation": "Kwei KA, et al. PLoS Genet. (2008) pmid: 18535672", "Include": "true"}, {"number": "66", "ReferenceId": "24476821", "FullCitation": "Nature (2014) pmid: 24476821", "Include": "true"}, {"number": "67", "ReferenceId": "25079552", "FullCitation": "Nature (2014) pmid: 25079552", "Include": "true"}, {"number": "68", "ReferenceId": "21720365", "FullCitation": "Nature (2011) pmid: 21720365", "Include": "true"}, {"number": "69", "ReferenceId": "32596145", "FullCitation": "Chen W, et al. Front Oncol (2020) pmid: 32596145", "Include": "true"}, {"number": "70", "ReferenceId": "30674866", "FullCitation": "Liu H, et al. Cell Death Dis (2019) pmid: 30674866", "Include": "true"}, {"number": "71", "ReferenceId": "32103545", "FullCitation": "Wang C, et al. FASEB J (2020) pmid: 32103545", "Include": "true"}, {"number": "72", "ReferenceId": "33300112", "FullCitation": "Plum PS, et al. J Cancer Res Clin Oncol (2021) pmid: 33300112", "Include": "true"}, {"number": "73", "ReferenceId": "23784465", "FullCitation": "Shen F, et al. Oncol. Rep. (2013) pmid: 23784465", "Include": "true"}, {"number": "74", "ReferenceId": "26505174", "FullCitation": "Song Y, et al. Exp Mol Pathol (2015) pmid: 26505174", "Include": "true"}, {"number": "75", "ReferenceId": "30633927", "FullCitation": "Shen W, et al. Hum Pathol (2019) pmid: 30633927", "Include": "true"}, {"number": "76", "ReferenceId": "23313142", "FullCitation": "Tian F, et al. Eur J Cancer (2013) pmid: 23313142", "Include": "true"}, {"number": "77", "ReferenceId": "31092103", "FullCitation": "Ma R, et al. Cancer Biol Ther (2019) pmid: 31092103", "Include": "true"}, {"number": "78", "ReferenceId": "34294813", "FullCitation": "Duan K, et al. Sci Rep (2021) pmid: 34294813", "Include": "true"}, {"number": "79", "ReferenceId": "27325420", "FullCitation": "Martinelli P, et al. Gut (2017) pmid: 27325420", "Include": "true"}, {"number": "80", "ReferenceId": "12502739", "FullCitation": "Kratochwil K, et al. Genes Dev. (2002) pmid: 12502739", "Include": "true"}, {"number": "81", "ReferenceId": "15256670", "FullCitation": "Scherz PJ, et al. Science (2004) pmid: 15256670", "Include": "true"}, {"number": "82", "ReferenceId": "14648664", "FullCitation": "Zaharieva BM, et al. J. Pathol. (2003) pmid: 14648664", "Include": "true"}, {"number": "83", "ReferenceId": "14499691", "FullCitation": "Arai H, et al. Cancer Genet. Cytogenet. (2003) pmid: 14499691", "Include": "true"}, {"number": "84", "ReferenceId": "24477574", "FullCitation": "Ribeiro IP, et al. Tumour Biol. (2014) pmid: 24477574", "Include": "true"}, {"number": "85", "ReferenceId": "22890726", "FullCitation": "Arao T, et al. Hepatology (2013) pmid: 22890726", "Include": "true"}, {"number": "86", "ReferenceId": "25822088", "FullCitation": "Schulze K, et al. Nat. Genet. (2015) pmid: 25822088", "Include": "true"}, {"number": "87", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "88", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "89", "ReferenceId": "25885470", "FullCitation": "Yamada T, et al. BMC Cancer (2015) pmid: 25885470", "Include": "true"}, {"number": "90", "ReferenceId": "26460955", "FullCitation": "Sang Y, et al. Oncotarget (2015) pmid: 26460955", "Include": "true"}, {"number": "91", "ReferenceId": "26344709", "FullCitation": "Hannah J, et al. Gene (2015) pmid: 26344709", "Include": "true"}, {"number": "92", "ReferenceId": "24522884", "FullCitation": "Sharma P, et al. Open Biol (2014) pmid: 24522884", "Include": "true"}, {"number": "93", "ReferenceId": "11849807", "FullCitation": "Gupta A, et al. Int. J. Radiat. Oncol. Biol. Phys. (2002) pmid: 11849807", "Include": "true"}, {"number": "94", "ReferenceId": "12393421", "FullCitation": "Li B, et al. Blood (2003) pmid: 12393421", "Include": "true"}, {"number": "95", "ReferenceId": "19929949", "FullCitation": "Hung MS, et al. J. Cell. Mol. Med. (2011) pmid: 19929949", "Include": "true"}, {"number": "96", "ReferenceId": "22422151", "FullCitation": "Ren S, et al. J. Mol. Med. (2012) pmid: 22422151", "Include": "true"}, {"number": "97", "ReferenceId": "24870930", "FullCitation": "Saucedo_Cuevas LP, et al. Oncotarget (2014) pmid: 24870930", "Include": "true"}, {"number": "98", "ReferenceId": "24305877", "FullCitation": "Wang Y, et al. Cancer Res. (2014) pmid: 24305877", "Include": "true"}, {"number": "99", "ReferenceId": "28223829", "FullCitation": "Sui X, et al. Onco Targets Ther (2017) pmid: 28223829", "Include": "true"}, {"number": "100", "ReferenceId": "19995430", "FullCitation": "Melchor L, et al. Breast Cancer Res. (2009) pmid: 19995430", "Include": "true"}, {"number": "101", "ReferenceId": "20556744", "FullCitation": "Castillo SD, et al. J. Pathol. (2010) pmid: 20556744", "Include": "true"}, {"number": "102", "ReferenceId": "26684807", "FullCitation": "Liu TT, et al. PLoS ONE (2015) pmid: 26684807", "Include": "true"}, {"number": "103", "ReferenceId": "26218750", "FullCitation": "Yang YL, et al. J. Cell. Mol. Med. (2015) pmid: 26218750", "Include": "true"}, {"number": "104", "ReferenceId": "27974468", "FullCitation": "Jia L, et al. J. Biol. Chem. (2017) pmid: 27974468", "Include": "true"}, {"number": "105", "ReferenceId": "9721878", "FullCitation": "Chen LC, et al. Cancer Res. (1998) pmid: 9721878", "Include": "true"}, {"number": "106", "ReferenceId": "17483321", "FullCitation": "Abba MC, et al. Cancer Res. (2007) pmid: 17483321", "Include": "true"}, {"number": "107", "ReferenceId": "17465225", "FullCitation": "Schindl M, et al. Anticancer Res. () pmid: 17465225", "Include": "true"}, {"number": "108", "ReferenceId": "27149990", "FullCitation": "Pfefferle AD, et al. Dis Model Mech (2016) pmid: 27149990", "Include": "true"}, {"number": "109", "ReferenceId": "25413624", "FullCitation": "Wang Y, et al. Mol. Cancer (2014) pmid: 25413624", "Include": "true"}, {"number": "110", "ReferenceId": "26840256", "FullCitation": "Deng J, et al. Oncotarget (2016) pmid: 26840256", "Include": "true"}, {"number": "111", "ReferenceId": "28442889", "FullCitation": "Gong Y, et al. Biologics (2017) pmid: 28442889", "Include": "true"}, {"number": "112", "ReferenceId": "27418574", "FullCitation": "Ren W, et al. Arch. Med. Res. (2016) pmid: 27418574", "Include": "true"}, {"number": "113", "ReferenceId": "12029633", "FullCitation": "Yasui K, et al. Hepatology (2002) pmid: 12029633", "Include": "true"}, {"number": "114", "ReferenceId": "26593394", "FullCitation": "Pan Y, et al. Sci Rep (2015) pmid: 26593394", "Include": "true"}, {"number": "115", "ReferenceId": "28576144", "FullCitation": "Huang G_, et al. BMC Cancer (2017) pmid: 28576144", "Include": "true"}, {"number": "116", "ReferenceId": "22447918", "FullCitation": "Birner P, et al. J. Clin. Pathol. (2012) pmid: 22447918", "Include": "true"}, {"number": "117", "ReferenceId": "26055549", "FullCitation": "Song J, et al. Int J Immunopathol Pharmacol (2015) pmid: 26055549", "Include": "true"}, {"number": "118", "ReferenceId": "26715273", "FullCitation": "Li X, et al. Tumour Biol. (2016) pmid: 26715273", "Include": "true"}, {"number": "119", "ReferenceId": "24420924", "FullCitation": "Xu Y, et al. J. Neurooncol. (2014) pmid: 24420924", "Include": "true"}, {"number": "120", "ReferenceId": "28677427", "FullCitation": "Yang Y, et al. Tumour Biol. (2017) pmid: 28677427", "Include": "true"}, {"number": "121", "ReferenceId": "23364677", "FullCitation": "Garc\u00eda MJ, et al. Mol. Cancer Ther. (2013) pmid: 23364677", "Include": "true"}, {"number": "122", "ReferenceId": "24648314", "FullCitation": "Yang YL, et al. J. Pathol. (2014) pmid: 24648314", "Include": "true"}, {"number": "123", "ReferenceId": "28095394", "FullCitation": "Englinger B, et al. Br. J. Cancer (2017) pmid: 28095394", "Include": "true"}, {"number": "124", "ReferenceId": "26969027", "FullCitation": "Hung MS, et al. J. Cell. Mol. Med. (2016) pmid: 26969027", "Include": "true"}, {"number": "125", "ReferenceId": "26503734", "FullCitation": "Hung MS, et al. Oncol. Rep. (2015) pmid: 26503734", "Include": "true"}, {"number": "126", "ReferenceId": "24368600", "FullCitation": "Wang Y, et al. Molecules (2013) pmid: 24368600", "Include": "true"}, {"number": "127", "ReferenceId": "17236138", "FullCitation": "Tekin M, et al. Am. J. Hum. Genet. (2007) pmid: 17236138", "Include": "true"}, {"number": "128", "ReferenceId": "10525310", "FullCitation": "Xie MH, et al. Cytokine (1999) pmid: 10525310", "Include": "true"}, {"number": "129", "ReferenceId": "25776529", "FullCitation": "Hagel M, et al. Cancer Discov (2015) pmid: 25776529", "Include": "true"}, {"number": "130", "ReferenceId": "12429977", "FullCitation": "Int. J. Oncol. (2002) pmid: 12429977", "Include": "true"}, {"number": "131", "ReferenceId": "23788652", "FullCitation": "Kan Z, et al. Genome Res. (2013) pmid: 23788652", "Include": "true"}, {"number": "132", "ReferenceId": "32111983", "FullCitation": "Li F, et al. Oncogene (2020) pmid: 32111983", "Include": "true"}, {"number": "133", "ReferenceId": "31063779", "FullCitation": "Caruso S, et al. Gastroenterology (2019) pmid: 31063779", "Include": "true"}, {"number": "134", "ReferenceId": "30518874", "FullCitation": "Gao L, et al. Oncogene (2019) pmid: 30518874", "Include": "true"}, {"number": "135", "ReferenceId": "21397858", "FullCitation": "Sawey ET, et al. Cancer Cell (2011) pmid: 21397858", "Include": "true"}, {"number": "136", "ReferenceId": "33674622", "FullCitation": "Kanzaki H, et al. Sci Rep (2021) pmid: 33674622", "Include": "true"}, {"number": "137", "ReferenceId": "28481359", "FullCitation": "Zehir A, et al. Nat. Med. (2017) pmid: 28481359", "Include": "true"}, {"number": "138", "ReferenceId": "22960745", "FullCitation": "Nature (2012) pmid: 22960745", "Include": "true"}, {"number": "139", "ReferenceId": "28988769", "FullCitation": "Robertson AG, et al. Cell (2017) pmid: 28988769", "Include": "true"}, {"number": "140", "ReferenceId": "22309595", "FullCitation": "Miura S, et al. BMC Cancer (2012) pmid: 22309595", "Include": "true"}, {"number": "141", "ReferenceId": "30815392", "FullCitation": "Kang HJ, et al. Liver Cancer (2019) pmid: 30815392", "Include": "true"}, {"number": "142", "ReferenceId": "25854696", "FullCitation": "Nagamatsu H, et al. Prostate (2015) pmid: 25854696", "Include": "true"}, {"number": "143", "ReferenceId": "31575541", "FullCitation": "Kim RD, et al. Cancer Discov (2019) pmid: 31575541", "Include": "true"}, {"number": "144", "ReferenceId": "27384874", "FullCitation": "Kaibori M, et al. Oncotarget (2016) pmid: 27384874", "Include": "true"}, {"number": "145", "ReferenceId": "31123723", "FullCitation": "Dumbrava EI, et al. JCO Precis Oncol (2018) pmid: 31123723", "Include": "true"}, {"number": "146", "ReferenceId": "26841866", "FullCitation": "Varier RA, et al. J. Biol. Chem. (2016) pmid: 26841866", "Include": "true"}, {"number": "147", "ReferenceId": "14651845", "FullCitation": "Hughes_Davies L, et al. Cell (2003) pmid: 14651845", "Include": "true"}, {"number": "148", "ReferenceId": "21409565", "FullCitation": "Cousineau I, et al. Mol. Genet. Genomics (2011) pmid: 21409565", "Include": "true"}, {"number": "149", "ReferenceId": "21735447", "FullCitation": "Wilkerson PM, et al. J. Pathol. (2011) pmid: 21735447", "Include": "true"}, {"number": "150", "ReferenceId": "18787609", "FullCitation": "van Hattem WA, et al. Int J Clin Exp Pathol (2008) pmid: 18787609", "Include": "true"}, {"number": "151", "ReferenceId": "16172393", "FullCitation": "Shih IeM, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 16172393", "Include": "true"}, {"number": "152", "ReferenceId": "23000897", "FullCitation": "Nature (2012) pmid: 23000897", "Include": "true"}, {"number": "153", "ReferenceId": "25631445", "FullCitation": "Nature (2015) pmid: 25631445", "Include": "true"}, {"number": "154", "ReferenceId": "18314909", "FullCitation": "Brown LA, et al. Genes Chromosomes Cancer (2008) pmid: 18314909", "Include": "true"}, {"number": "155", "ReferenceId": "19636701", "FullCitation": "Brown LA, et al. Breast Cancer Res. Treat. (2010) pmid: 19636701", "Include": "true"}, {"number": "156", "ReferenceId": "20349280", "FullCitation": "Altinisik J, et al. Mol. Biol. Rep. (2011) pmid: 20349280", "Include": "true"}, {"number": "157", "ReferenceId": "24641409", "FullCitation": "Madjd Z, et al. Asian Pac. J. Cancer Prev. (2014) pmid: 24641409", "Include": "true"}, {"number": "158", "ReferenceId": "21327470", "FullCitation": "Bane AL, et al. Breast Cancer Res. Treat. (2011) pmid: 21327470", "Include": "true"}, {"number": "159", "ReferenceId": "15355907", "FullCitation": "Rodriguez C, et al. Clin. Cancer Res. (2004) pmid: 15355907", "Include": "true"}, {"number": "160", "ReferenceId": "21487248", "FullCitation": "Dedes KJ, et al. Cell Cycle (2011) pmid: 21487248", "Include": "true"}, {"number": "161", "ReferenceId": "23729402", "FullCitation": "Ihnen M, et al. Mol. Cancer Ther. (2013) pmid: 23729402", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_09_11 00:09:53", "OpName": "Giles Maule, M.D., Ph.D | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Giles Maule, M.D., Ph.D | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "862x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "0 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "ANUS", "disease_ontology": "Anus squamous cell carcinoma", "flowcell_analysis": "2000023460", "gender": "male", "pathology_diagnosis": "Squamous cell carcinoma", "percent_tumor_nuclei": "30", "pipeline_version": "v3.14.0", "purity_assessment": "56.3", "specimen": "ORD_1445643_01*US1385415.01", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1445643_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Anus", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "874.37", "name": "SQ_US1385415.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.4258", "cds_effect": "6915_6917delCAG", "depth": "1099", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "SPEN", "percent_reads": "42.58", "position": "chr1:16259649", "protein_effect": "S2306del", "status": "unknown", "strand": "+", "transcript": "NM_015001", "dna_evidence": {"sample": "SQ_US1385415.01_1"}}, {"allele_fraction": "0.49", "cds_effect": "371T>C", "depth": "498", "equivocal": "false", "functional_effect": "missense", "gene": "POLD1", "percent_reads": "49.0", "position": "chr19:50905089", "protein_effect": "V124A", "status": "unknown", "strand": "+", "transcript": "NM_002691", "dna_evidence": {"sample": "SQ_US1385415.01_1"}}, {"allele_fraction": "0.6648", "cds_effect": "1534G>A", "depth": "874", "equivocal": "false", "functional_effect": "missense", "gene": "IRS2", "percent_reads": "66.48", "position": "chr13:110436867", "protein_effect": "A512T", "status": "unknown", "strand": "_", "transcript": "NM_003749", "dna_evidence": {"sample": "SQ_US1385415.01_1"}}, {"allele_fraction": "0.1817", "cds_effect": "1328G>A", "depth": "622", "equivocal": "false", "functional_effect": "missense", "gene": "MKNK1", "percent_reads": "18.17", "position": "chr1:47024317", "protein_effect": "R443H", "status": "unknown", "strand": "_", "transcript": "NM_003684", "dna_evidence": {"sample": "SQ_US1385415.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "10", "equivocal": "false", "gene": "EMSY", "number_of_exons": "20 of 20", "position": "chr11:76157953_76310898", "ratio": "2.51", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1385415.01_1"}}, {"copy_number": "10", "equivocal": "false", "gene": "EED", "number_of_exons": "13 of 13", "position": "chr11:85956263_85989568", "ratio": "2.58", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1385415.01_1"}}, {"copy_number": "8", "equivocal": "true", "gene": "FGF3", "number_of_exons": "3 of 3", "position": "chr11:69580315_69666638", "ratio": "1.89", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1385415.01_1"}}, {"copy_number": "8", "equivocal": "true", "gene": "CCND1", "number_of_exons": "5 of 5", "position": "chr11:69412013_69502020", "ratio": "1.96", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1385415.01_1"}}, {"copy_number": "8", "equivocal": "true", "gene": "GATA6", "number_of_exons": "6 of 6", "position": "chr18:19751105_19780786", "ratio": "1.95", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1385415.01_1"}}, {"copy_number": "8", "equivocal": "true", "gene": "FGF19", "number_of_exons": "3 of 3", "position": "chr11:69514029_69561786", "ratio": "1.84", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1385415.01_1"}}, {"copy_number": "8", "equivocal": "true", "gene": "FGF4", "number_of_exons": "3 of 3", "position": "chr11:69588076_69589852", "ratio": "1.84", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1385415.01_1"}}, {"copy_number": "8", "equivocal": "true", "gene": "MEN1", "number_of_exons": "9 of 9", "position": "chr11:64433069_64713615", "ratio": "1.84", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1385415.01_1"}}, {"copy_number": "8", "equivocal": "true", "gene": "CUL4A", "number_of_exons": "20 of 20", "position": "chr13:113863941_113917913", "ratio": "2.01", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1385415.01_1"}}]}, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "0.0", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": {"non_human": {"organism": "HPV_16", "reads_per_million": "5154", "status": "likely", "dna_evidence": {"sample": "SQ_US1385415.01_1"}}}}}}}